Guardant Health (GH) Stock Forecast & Price Target

$21.92

-1.02 (-4.45%)

(As of 11:16 AM ET)

Guardant Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
1

Buy
15

Based on 16 Wall Street analysts who have issued ratings for Guardant Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 1 has given a hold rating, and 15 have given a buy rating for GH.

Consensus Price Target

$39.67
73.22% Upside

According to the 16 analysts' twelve-month price targets for Guardant Health, the average price target is $39.67. The highest price target for GH is $50.00, while the lowest price target for GH is $27.00. The average price target represents a forecasted upside of 73.22% from the current price of $21.92.

Get the Latest News and Ratings for GH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Guardant Health and its competitors.

GH Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	15 Buy rating(s)	17 Buy rating(s)	13 Buy rating(s)	15 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$39.67	$39.31	$36.83	$55.44
Forecasted Upside	73.22% Upside	53.68% Upside	29.65% Upside	89.98% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

Massive NVIDIA Sell-Off: Are We Headed for a Market Collapse? (Ad)

You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning...

Click here for his urgent warning - and 4 steps you need to take today to protect your retirement to

GH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Guardant Health Stock vs. The Competition

Type	Guardant Health	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	73.22% Upside	821.78% Upside	6.67% Upside
News Sentiment Rating	Positive News See Recent GH News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/21/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$32.00 ➝ $40.00	+42.30%
8/13/2024	Piper Sandler 2 of 5 stars		Boost Target	Overweight ➝ Overweight	$30.00 ➝ $34.00	+11.73%
8/8/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+48.27%
8/8/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$41.00 ➝ $42.00	+38.61%
8/8/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$45.00 ➝ $48.00	+58.00%
8/8/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $37.00	+21.79%
Get the Latest News and Ratings for GH and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.
7/30/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$45.00 ➝ $50.00	+37.51%
7/18/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $40.00	+22.89%
7/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$28.00 ➝ $32.00	-1.33%
6/28/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Nambi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$36.00	+23.92%
6/4/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$30.00 ➝ $38.00	+38.13%
6/3/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$32.00	+17.09%
5/24/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$44.00 ➝ $44.00	+79.01%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Peer Perform
11/13/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$27.00	+25.12%
11/8/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$55.00 ➝ $50.00	+111.24%
9/28/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$34.00	+23.10%
9/8/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
5/10/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$60.00 ➝ $55.00	+129.26%
2/24/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$70.00 ➝ $53.00	+104.95%
1/4/2023	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Sector Outperform	$36.00	+34.83%
11/4/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$110.00 ➝ $83.00	+84.12%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:36 AM ET.

GH Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Guardant Health is $39.67, with a high forecast of $50.00 and a low forecast of $27.00.
: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There is currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GH shares.
: According to analysts, Guardant Health's stock has a predicted upside of 80.96% based on their 12-month stock forecasts.
: Guardant Health has been rated by research analysts at Bank of America, BTIG Research, Citigroup, Craig Hallum, JPMorgan Chase & Co., Piper Sandler, TD Cowen, The Goldman Sachs Group, and UBS Group in the past 90 days.
: Analysts like Guardant Health more than other "medical" companies. The consensus rating score for Guardant Health is 2.94 while the average consensus rating score for "medical" companies is 2.78. Learn more on how GH compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Massive NVIDIA Sell-Off: Are We Headed for a Market Collapse? (Ad)

You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this year. But here's what's even more concerning...

Click here for his urgent warning - and 4 steps you need to take today to protect your retirement to

This page (NASDAQ:GH) was last updated on 10/1/2024 by MarketBeat.com Staff

From Our Partners